News Releases

06/02/21 CytRx to Present at Upcoming Investor Conferences
05/13/21 CytRx Comments on Quarterly Results and Year-to-Date Progress
05/07/21 CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
04/01/21 CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
03/25/21 CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress
03/08/21 CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
03/04/21 CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
03/03/21 CytRx to Participate in Upcoming Investor Conferences
02/11/21 CytRx is Added to the LD Micro Index
12/31/20 CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
12/22/20 CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
12/07/20 CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
11/16/20 CytRx Comments on Quarterly Results and Recent Strategic Progress
11/11/20 CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
10/27/20 CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol
10/13/20 CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment
10/07/20 CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer
09/30/20 CytRx Issues Statement Regarding Orphazyme’s Global Offering
09/17/20 CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C
09/03/20 CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation
08/24/20 CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities
08/13/20 CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign
08/10/20 CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
07/21/20 CytRx Corporation Highlights Orphazyme’s Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
07/20/20 CytRx Corporation Highlights Orphazyme’s Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson’s Disease Research
06/29/20 CytRx Corporation Highlights Orphazyme’s Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
06/01/20 CytRx Corporation Highlights Orphazyme’s Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
05/26/20 CytRx Corporation Highlights Orphazyme’s Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
05/21/20 CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
04/29/20 CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
03/10/20 CytRx Corporation Provides Update on Management Change
02/28/20 CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
02/11/20 CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
02/04/20 CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
01/29/20 CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
12/19/19 CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
08/09/19 CytRx Corporation Reports Second Quarter 2019 Financial Results
07/30/19 CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
07/22/19 CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
06/27/19 CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
06/26/19 CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
06/19/19 CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
05/31/19 CytRx Corporation to Commence Trading on OTCQB Venture Market
05/15/19 CytRx Corporation Reports First Quarter 2019 Financial Results
05/08/19 CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
05/02/19 CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
04/29/19 CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
03/29/19 CytRx Corporation Reports 2018 Financial Results
03/12/19 CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
02/13/19 CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
02/11/19 CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
02/06/19 CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
01/14/19 CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
12/21/18 CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
11/28/18 CytRx Corporation to Present at the 11th Annual LD Micro Main Event
11/08/18 CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
11/02/18 CytRx Corporation Reports Third Quarter 2018 Financial Results
10/31/18 Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
10/29/18 CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
09/25/18 CytRx Corporation to Present at the 2018 MicroCap Conference
09/13/18 CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
08/27/18 CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
08/06/18 CytRx Corporation Reports Second Quarter 2018 Financial Results
08/01/18 CytRx Corporation Pays Off Balance of Outstanding Debt
07/30/18 CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
07/25/18 CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application
07/23/18 CytRx Corporation Announces Expiration of Outstanding Warrants
07/16/18 CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
06/28/18 CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
06/25/18 CytRx Corporation Joins Russell Microcap® Index
06/21/18 CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology
06/07/18 CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
06/04/18 CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates
05/30/18 CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference
05/17/18 CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
05/15/18 CytRx Announces Closing of $7.0 Million Registered Direct Offering
05/11/18 CytRx Announces $7.0 Million Registered Direct Offering
05/08/18 CytRx Reports First Quarter 2018 Financial Results
05/07/18 CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018
05/03/18 CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
04/30/18 CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting
04/18/18 CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
04/09/18 CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference
03/19/18 CytRx Reports 2017 Financial Results
03/16/18 CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
03/15/18 CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
03/12/18 CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
03/05/18 CytRx to Present at the 30th Annual ROTH Conference
03/01/18 CytRx Announces Key Addition to Corporate Development Team
02/28/18 CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates
02/22/18 CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
02/06/18 CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference
02/05/18 CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
01/17/18 CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
01/03/18 CytRx Corporation to Present at Biotech Showcase 2018